BAX · Baxter International Inc.

Baxter’s Q1 2026 results reflect continued operational strain following major strategic actions — notably the January 2025 divestiture of Kidney Care and integration of Hill-Rom — with GAAP earnings collapsing into a $17 million loss from continuing operations, or ($0.03) per diluted share, versus $64 million and $0.13 in Q1 2025. The decline stems not from revenue weakness — reported sales rose 3% to $2.7 billion — but from $112 million in special items (including $146 million in intangible amortization, $68 million in business optimization costs, and $98 million in Hurricane Helene remediation in the prior year that did not recur), alongside margin pressure: gross margin held at 33.0% but SG&A rose to 27.0% of sales, and R&D dipped slightly. Management explicitly attributes the 35% drop in adjusted EPS to an unfavorable prior-year comparison involving expense reclassification and elevated tariff and manufacturing costs. Segment performance was mixed: Pharmaceuticals grew 7% on strong Drug Compounding (+30%), but Infusion Therapies & Technologies fell 5% organically due to the Novum IQ LVP hold — a known quality-related constraint cited in prior filings. The reaffirmed full-year guidance — flat organic growth and $1.85–$2.05 adjusted EPS — signals management’s confidence in stabilization efforts, including over 230 new GPS continuous improvement initiatives launched in Q1. Critically, the $0.01 dividend declaration confirms the company’s materially reduced capital return posture post-divestiture and amid high debt service obligations, underscoring liquidity discipline over shareholder returns. Free cash flow turned positive ($76M vs. -$221M in Q1 2025), yet capital expenditures increased, reflecting ongoing investment in business transformation — a theme reinforced by $11 million in newly disclosed transformation costs. Forward-looking risks remain acute, per the press release’s extensive forward-looking statements section, covering supply chain, AI integration, regulatory compliance, and geopolitical exposure — all of which constrain near-term predictability despite the stable guidance band.